PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsHodgkin disease
MeSH D006689 - hodgkin disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D008223:Lymphoma
$
Success rate
D006689: 
Hodgkin disease
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaBleomycin Bleomycin  1996-06-01   
Doxorubicin Doxorubicin  1995-07-28   
Ifosfamide, Mesna Ifosfamide/mesna  2002-02-26   
Doxorubicin Myocet (previously Myocet)  2000-07-13   
Cyclophosphamide Neosar  1993-04-29   
Vincristine Vincasar  1987-07-17   
Vincristine Vincristine  1999-09-01   
Vinorelbine Vinorelbine  2003-02-03   
Cisplatin Cisplatin  2000-05-16   
Meitheal PharmaceuticalsDacarbazine Dacarbazine  1998-08-27   
Bleomycin Bleomycin  2018-04-20   
Carmustine Carmustine  2021-08-02   
Ifosfamide Ifosfamide  2007-04-04   
Novast LaboratoriesVinorelbine Vinorelbine  2019-08-05   
IngenusCarmustine Carmustine  2022-06-21   
Cyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
MylanDoxorubicin Doxorubicin  2011-10-28   
Ifosfamide Ifosfamide  2012-11-26   
Carmustine Carmustine  2023-03-03   
Cisplatin Cisplatin  2012-04-18   
Rising PharmaceuticalsVinorelbine Vinorelbine  2012-08-31   
CiplaBleomycin Bleomycin  2019-03-11   
Cyclophosphamide Cyclophosphamide  2019-01-18   
Merck Sharp & DohmePembrolizumab Keytruda  2014-09-04 $26,163 M Q2/23-Q1/24 
BayerDacarbazine Dtic-dome  1982-01-01   
PfizerDoxorubicin Adriamycin  1991-01-30   
Doxorubicin Doxorubicin  1982-01-01   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
59%
118/201
Phase 2
32%
57/180
Phase 3
47%
41/88
Approved: 26Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use